ANTI-FOLR1 IMMUNOCONJUGATE APPLICATION SCHEMES Russian patent published in 2023 - IPC A61K39/395 A61K47/64 A61P35/00 

FIELD: medicine.

SUBSTANCE: group of inventions relates to a method of treating a human patient with FOLR1-expressing cancer which includes administering to the patient an immunoconjugate that binds to a FOLR1 polypeptide, the said immunoconjugate containing an antibody or its antigen-binding fragment containing a complementarity-determining region (CDR)-1 variable light chain (VL) according to SEQ ID NO: 6, CDR-2 VL according to SEQ ID NO: 7, CDR-3 VL according to SEQ ID NO: 8, Variable heavy chain (VH) CDR-1 according to SEQ ID NO: 9, CDR-2 VH according to SEQ ID NO: 11, CDR-3 VH according to SEQ ID NO: 12 and maytansinoid, wherein the said immunoconjugate is administered at a dose of 5 milligrams (mg) per kilogram (kg) of adjusted ideal body weight (AIBW) of a patient, also relates to a method of treating a human patient having FOLR1-expressing cancer comprising administering the composition to the patient containing immunoconjugates that bind to a FOLR1 polypeptide, the said immunoconjugates containing an average of 3–4 DM4 maytansinoid per antibody containing (i) a heavy chain containing the same amino acid sequence as the heavy chain amino acid sequence encoded by the plasmid deposited in the American Type Culture Collection (ATCC) number PTA-10772, and (ii) a light chain containing the same amino acid sequence as the amino acid sequence of the light chain encoded by the plasmid deposited at ATCC number PTA-10774, wherein the DM4 maytansinoids are linked to the antibody via sulfo-SPDB, wherein the immunoconjugates are administered at a dose of 5 milligrams (mg) per kilogram (kg) of the patient's adjusted ideal body weight (AIBW) once every three weeks, and also relates to a method of treating a human patient having FOLR1-expressing cancer, comprising administering to a patient a composition containing immunoconjugates that bind to a FOLR1 polypeptide, the said immunoconjugates containing 3–4 DM4 maytansinoid per antibody containing (i) a heavy chain variable domain comprising SEQ ID NO: 3 and (ii) a light chain variable domain comprising SEQ ID NO: 5 wherein DM4 maytansinoids are bound to the antibody via sulfo-SPDB and the immunoconjugates are administered at a dose of 5 milligrams (mg) per kilogram (kg) of the patient's adjusted ideal body weight (AIBW) once every three weeks, and also applies to the uses of immunoconjugates that bind to a FOLR1 polypeptide in the treatment of FOLR1-expressing cancer.

EFFECT: group of inventions provides reduction of ophthalmic toxicity.

96 cl, 13 dwg, 3 tbl, 6 ex